231 related articles for article (PubMed ID: 20844582)
1. Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.
Cai Q; Robertson ES
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844582
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.
Cai Q; Verma SC; Kumar P; Ma M; Robertson ES
PLoS One; 2010 Mar; 5(3):e9720. PubMed ID: 20300531
[TBL] [Abstract][Full Text] [Related]
3. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.
Groulx I; Lee S
Mol Cell Biol; 2002 Aug; 22(15):5319-36. PubMed ID: 12101228
[TBL] [Abstract][Full Text] [Related]
4. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
5. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
[TBL] [Abstract][Full Text] [Related]
6. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
7. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
8. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.
van Hagen M; Overmeer RM; Abolvardi SS; Vertegaal AC
Nucleic Acids Res; 2010 Apr; 38(6):1922-31. PubMed ID: 20026589
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
[TBL] [Abstract][Full Text] [Related]
10. TCTP increases stability of hypoxia-inducible factor 1α by interaction with and degradation of the tumour suppressor VHL.
Chen K; Chen S; Huang C; Cheng H; Zhou R
Biol Cell; 2013 May; 105(5):208-218. PubMed ID: 23387829
[TBL] [Abstract][Full Text] [Related]
11. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
13. K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.
Metcalf JL; Bradshaw PS; Komosa M; Greer SN; Stephen Meyn M; Ohh M
Oncogene; 2014 Feb; 33(8):1055-65. PubMed ID: 23455319
[TBL] [Abstract][Full Text] [Related]
14. pVHL mediates K63-linked ubiquitination of nCLU.
Xue J; Lv DD; Jiao S; Zhao W; Li X; Sun H; Yan B; Fan L; Hu RG; Fang J
PLoS One; 2012; 7(4):e35848. PubMed ID: 22532874
[TBL] [Abstract][Full Text] [Related]
15. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
Lee S; Chen DY; Humphrey JS; Gnarra JR; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1770-5. PubMed ID: 8700833
[TBL] [Abstract][Full Text] [Related]
16. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Paltoglou S; Roberts BJ
Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
[TBL] [Abstract][Full Text] [Related]
17. Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor.
Khacho M; Mekhail K; Pilon-Larose K; Payette J; Lee S
Mol Cell Biol; 2008 Jan; 28(1):302-14. PubMed ID: 17967880
[TBL] [Abstract][Full Text] [Related]
18. Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway.
Chung J; Roberts AM; Chow J; Coady-Osberg N; Ohh M
Oncogene; 2006 May; 25(21):3079-83. PubMed ID: 16407835
[TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
20. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
